# US 6,730,776 B1 · WF14573 or its salt, production thereof and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,776 B1
- Document ID: US6730776B1
- Status: Granted
- Kind: B1
- Application number: 09/646,342
- Filed: 2000-09-18
- Granted: 2004-05-04
- Earliest claimed: 1998-03-16
- Assignees: Fujisawa Pharmaceutical Co., Ltd.
- Inventors: Yasuhiro Hori; Shigehiro Takase; Yasuhisa Tsurumi; Michizane Hashimoto; Motohiro Hino
- Web page: https://patentgrep.com/patent/US6730776B1

## CPC

- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a new antimicrobial compound WF14573, and a process for producing WF14573 by (a) culturing a WF14573A and/or B-producing microorganism in a nutrient medium and recovering WF14573A and/or B from the resultant cultured broth or (b) deacylating WF14573A and/or B in the presence of a microbial substance which is capable of deacylating WF14573A and/or B. Also provided are an antimicrobial agent comprising WF14573 and carrier(s), a pharmaceutical composition comprising an effective amount of WF14573 and pharmaceutically acceptable carrier(s), a method for killing microorganisms by applying WF14573 to the microorganisms, and use of WF14573 for the treatment of infectious diseases caused by pathogenic microorganisms.

## Claims

### Claim 1

A compound of formula (I):
wherein R1 is hydrogen or methyl and R2 is hydrogen or acyl, or a salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is hydrogen and R2 is palmitoyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R1 is methyl and R2 is palmitoyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is hydrogen and R2 is hydrogen.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is methyl and R2 is hydrogen.

### Claim 6 (depends on 1)

A salt of the compound of claim 1.

### Claim 7 (depends on 1)

A composition comprising the compound of claim 1 and optionally, one or more auxiliary agent(s), stabilizing agent(s), thickening agent(s), coloring agent(s), perfume(s), preservative(s) or bacteriostatic agent(s).

### Claim 8 (depends on 7)

The composition of claim 7 in combination with a pharmaceutically acceptable carrier or excipient.

### Claim 9 (depends on 7)

The composition of claim 7, further comprising one or more auxiliary agent(s), stabilizing agent(s), thickening agent(s), coloring agent(s), or perfume(s).

### Claim 10 (depends on 7)

The composition of claim 7, further comprising one or more preservative(s) or bacteriostatic agent(s).

### Claim 11 (depends on 7)

The composition of claim 7 in the form of a tablet, pellet, or capsule.

### Claim 12 (depends on 7)

The composition of claim 7 in the form of a solution, emulsion or suspension.

### Claim 13 (depends on 7)

The composition of claim 7 in the form of a suppository or ointment.

### Claim 14 (depends on 1)

A method for inhibiting the growth of a yeast or fungus comprising contacting a yeast or fungus with an amount of the compound of claim 1 effective to inhibit the growth of said yeast or fungus.

### Claim 15 (depends on 14)

The method of claim 14, wherein said yeast or fungus is Candida.

### Claim 16 (depends on 14)

The method of claim 14, wherein said yeast or fungus is Aspergillus.

### Claim 17 (depends on 14)

The method of claim 14, wherein said yeast or fungus is Cryptococcus.

### Claim 18

A process for producing a compound of formula (I):
wherein R1 is hydrogen or methyl and R2 is hydrogen or palmitoyl, or a salt thereof, comprising:
(a) culturing a microorganism that produces the compound of formula (I) or a salt thereof, and
(b) recovering the compound of formula (I) or a salt thereof.

### Claim 19 (depends on 18)

The process of claim 18, wherein said microorganism is Coleophoma.

### Claim 20 (depends on 18)

The process of claim 18, wherein said microorganism is Coleophoma empetri.

### Claim 21 (depends on 18)

The process of claim 18, wherein said microorganism is Coleophoma empetri No. 14573.

### Claim 22

A process for producing the compound of formula (I):
wherein R1 is hydrogen or methyl and R2 is hydrogen, or a salt thereof comprising:
deacylating a compound of formula (I) by using deacylase, wherein R2 is palmitoyl and
recovering the compound of formula (I) wherein R1 is hydrogen or methyl and R2 is hydrogen, or a salt thereof.

### Claim 23 (depends on 22)

The process of claim 22, comprising contacting said compound of formula (I), wherein R2 is palmitoyl with a microorganism to deacylate said compound.

### Claim 24 (depends on 22)

The process of claim 22, comprising contacting said compound of formula (I), wherein R2 is palmitoyl, with Streptomyces to deacylate said compound.

### Claim 25 (depends on 14)

The method of claim 14, comprising intravenously administering to a subject in need thereof an amount of said compound effective to inhibit the growth of said yeast or fungus.

### Claim 26 (depends on 14)

The method of claim 14, comprising intramuscularly administering to a subject in need thereof an amount of said compound effective to inhibit the growth of said yeast or fungus.

### Claim 27 (depends on 14)

The method of claim 14, comprising orally administering to a subject in need thereof an amount of said compound effective to inhibit the growth of said yeast or fungus.

### Claim 28 (depends on 14)

The method of claim 14, comprising percutaneously administering to a subject in need thereof an amount of said compound effective to inhibit the growth of said yeast or fungus.
